ClinicalTrials.gg
TerminatedNCT00539968Updated Feb 5, 2015

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

A Phase 1/2 interventional study of Docetaxel plus lonafarnib in Prostate Cancer, Breast Cancer and Ovarian Cancer, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 193 studies testing docetaxel in Prostatic Neoplasms — 15 open to participants now, 24 under way, 10 of them phase 3. Docetaxel · Prostatic Neoplasms.

Enrollment
168th of 185
5 · median 39
Started
2007
with 19 others
Phase 1/2
23 of 193
3 open now
Registered
98th of 193
by date

Among the 193 studies testing docetaxel in Prostatic Neoplasms, this one is the 168th largest by enrollment of the 185 interventional ones that give a count, is one of 20 that started in 2007, is one of 23 in phase 1/2, and was the 98th registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 193 studies testing docetaxel in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies testing docetaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible. A second part of the study will further examine the effectiveness of the combination treatment in men with prostate cancer.

03

Conditions studied

  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Gastric Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part 1: Subjects may be male or female and must be at least 18 years of age.
  • For Part 1: Cancer for which docetaxel treatment is appropriate.
  • For Part 1: Docetaxel-naïve
  • For Part 2: Subjects must be male and at least 18 years of age.
  • For Part 2: Subjects must have adenocarcinoma of the prostate confirmed by histologic/cytologic .
  • For Part 2: Subjects must have progressive, , AIPC and a PSA of 10 ng/ml or more after hormonal therapy prior to docetaxel treatment. Progressive disease is defined as a consistently increasing serum PSA level within 28 days prior to docetaxel administration.
  • Adequate organ function within 3 weeks prior to first study drug administration.
  • Performance status () is less than or equal to 2.
  • Subject understands and agrees to procedures and participation by signing form.
  • Agrees to use medically accepted form of .

Exclusion criteria

Exclusion Criteria:

  • Receipt of or need to continue to receive prohibited medications (listed in the protocol) more recently than the (indicated in the protocol).
  • Surgery within 3 weeks prior to first study drug administration.
  • History within 5 years prior to first study drug administration of another except adequately treated Stage I/II basal/squamous cell skin cancer.
  • Radiation therapy to more than 25% of his/her total bone marrow during life.
  • Radiation therapy within 3 weeks prior to first study drug administration.
  • Known to prednisone, docetaxel, polysorbate 80, lonafarnib, or any associated with these medications.
  • Known to use.
  • Known or .
  • Heart, vascular, or seizure disorder (detailed list in the protocol) within 6 months prior to first study drug administration.
  • Baseline greater than 450 msec.
  • Grade 2 or more peripheral neuropathy or drug-related toxicity per . Exceptions are noted in the protocol.
  • Any condition or situation that the investigator thinks would interfere with the study evaluations or subject's participation.
  • Subject is part of staff personnel involved in the study.
  • Subject has known clinically significant .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Docetaxel plus lonafarnib (single arm)

    Docetaxel plus lonafarnib

    Drug: Docetaxel plus lonafarnib

Interventions

  • DrugDocetaxel plus lonafarnib

    Drug pages: Docetaxel · Lonafarnib

    Docetaxel: 60-75 mg/m2 Lonafarnib: 150-375 mg PO BID

    Also known as: Docetaxel (Taxotere®); lonafarnib (SCH 066336, Sarasar®)

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and dose-limiting toxicities

    Time frame: Until disease progression, unacceptable dose delays or reductions, or unacceptable toxicity

  2. Rate of prostate-specific antigen (PSA) responses

    Time frame: Until disease progression, unacceptable dose delays or reductions, or unacceptable toxicity

Secondary outcomes

  1. Proportion of subjects with dose-limiting toxicities

    Time frame: Until disease progression, unacceptable dose delays or reductions, or unacceptable toxicity

  2. Plasma lonafarnib concentrations

    Time frame: Until disease progression, unacceptable dose delays or reductions, or unacceptable toxicity

  3. RECIST-defined radiological response rate

    Time frame: Until disease progression, unacceptable dose delays or reductions, or unacceptable toxicity

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 5, 2007
Start
Jun 2007
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Last update
Feb 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00539968
Responsible party
Sponsor
First posted
Oct 5, 2007
Start date
Jun 2007
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Feb 5, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Lonafarnib

Start the discussion